Indivior Statement on the Opiant Pharmaceutical Acquisition

The opioid addiction crisis continues to devastate our families and communities. Opiant’s nalmefene rescue therapy medication, which is currently not approved by the FDA, will be an important additional option to help those who suffer an opioid overdose, and with Indivior’s and Opiant’s combined resources and expertise we can launch this therapy, when approved, more effectively.  Together our companies can fight this problem. 

Nina DeLorenzo, Chief Global Impact Officer